StockData
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD) stock

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.01−0.60 (-16.62%)

Close on Nov 17, 2026Market cap $321.08MP/E –Yield –

Relmada Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Relmada Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$45.99M. For fiscal 2025 it was -$45.79M. The highest annual figure on record is -$1.58M in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$45.79M–
FY2024Dec 31, 2024-$51.76M–
FY2023Dec 31, 2023-$51.66M–
FY2022Dec 31, 2022-$103.80M–
FY2021Dec 31, 2021-$91.87M–
FY2019Jun 30, 2019-$10.50M–
FY2018Jun 30, 2018-$6.00M–
FY2017Jun 30, 2017-$6.47M–
FY2016Jun 30, 2016-$13.14M–
FY2013Dec 31, 2013-$2.24M–
FY2012Dec 31, 2012-$1.58M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$9.61M–
Q1 FY2026CQ1 2026Mar 31, 2026-$15.07M–
Q4 FY2025CQ4 2025Dec 31, 2025-$14.60M–
Q3 FY2025CQ3 2025Sep 30, 2025-$6.72M–
Q2 FY2025CQ2 2025Jun 30, 2025-$6.40M–
Q1 FY2025CQ1 2025Mar 31, 2025-$18.07M–
Q4 FY2024CQ4 2024Dec 31, 2024-$8.80M–
Q3 FY2024CQ3 2024Sep 30, 2024-$16.66M–
Q2 FY2024CQ2 2024Jun 30, 2024-$13.26M–
Q1 FY2024CQ1 2024Mar 31, 2024-$13.04M–
Q4 FY2023CQ4 2023Dec 31, 2023-$10.25M–
Q3 FY2023CQ3 2023Sep 30, 2023-$11.63M–
Q2 FY2023CQ2 2023Jun 30, 2023-$13.27M–
Q1 FY2023CQ1 2023Mar 31, 2023-$16.51M–
Q4 FY2022CQ4 2022Dec 31, 2022-$35.88M–
Q1 FY2022CQ1 2022Mar 31, 2022-$19.43M–
Q4 FY2021CQ4 2021Dec 31, 2021-$37.66M–
Q3 FY2021CQ3 2021Sep 30, 2021-$20.92M–
Q2 FY2021CQ2 2021Jun 30, 2021-$17.21M–
Q1 FY2021CQ1 2021Mar 31, 2021-$16.09M–
Q4 FY2019CQ2 2019Jun 30, 2019-$3.67M–
Q3 FY2019CQ1 2019Mar 31, 2019-$2.01M–
Q2 FY2019CQ4 2018Dec 31, 2018-$3.15M–
Q1 FY2019CQ3 2018Sep 30, 2018-$1.67M–
Q4 FY2018CQ2 2018Jun 30, 2018-$2.27M–
Q3 FY2018CQ1 2018Mar 31, 2018-$1.63M–
Q2 FY2018CQ4 2017Dec 31, 2017-$1.13M–
Q1 FY2018CQ3 2017Sep 30, 2017-$979.05K–
Q4 FY2017CQ2 2017Jun 30, 2017-$1.02M–
Q3 FY2017CQ1 2017Mar 31, 2017-$1.86M–
Q2 FY2017CQ4 2016Dec 31, 2016-$1.45M–
Q1 FY2017CQ3 2016Sep 30, 2016-$2.14M–
Q4 FY2016CQ2 2016Jun 30, 2016-$2.83M–
Q3 FY2016CQ1 2016Mar 31, 2016-$3.63M–
Q2 FY2016CQ4 2015Dec 31, 2015-$3.48M–
Q1 FY2016CQ3 2015Sep 30, 2015-$3.22M–
Q3 FY2013CQ3 2013Sep 30, 2013-$408.70K–

More Relmada Therapeutics figures

See a number that looks wrong?